

Special Issue

Emerging Perspectives on Breast Cancer and Antibody–Drug Conjugates Treatment: From Bench to Bedside

Message from the Guest Editor

In recent years, the therapeutic landscape of breast cancer has transitioned from broad-spectrum chemotherapies to precision-targeted treatments, rendering the path to optimizing patient outcomes increasingly complex. Antibody–drug conjugates (ADCs) stand out as a pioneering treatment strategy, promising a transformation in breast cancer care. ADCs embody the epitome of oncological innovation. Their innovative design, characterized by targeted drug delivery, offers a novel paradigm in cancer therapeutics. This Special Issue, entitled "Emerging Perspectives on Breast Cancer and Antibody–Drug Conjugates Treatment: from Bench to Bedside", aims to explore the depths of knowledge surrounding ADCs in the preclinical and clinical arena. We welcome the submission of insightful research articles and reviews that delve into mechanisms of action, biomarker identification, and toxicity management, and those that aim to unravel resistance patterns and strategize treatment pathways. Our aim is to present a comprehensive overview of the field while promoting a more profound and holistic understanding of the topic.

Guest Editor

Dr. Alberto Zambelli

1. Medical Oncology and Hematology Unit, IRCCS Humanitas Research Hospital, 20089 Rozzano, Italy
2. Department of Biomedical Sciences, Humanitas University, 20072 Pieve Emanuele, Italy

Deadline for manuscript submissions

closed (31 August 2024)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/183815

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPLus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).